329 related articles for article (PubMed ID: 32867726)
1. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
2. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
3. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
5. Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid.
Bixby B; Vrba L; Lenka J; Oshiro MM; Watts GS; Hughes T; Erickson H; Chopra M; Knepler JL; Knox KS; Jarnagin L; Alalawi R; Kala M; Bernert R; Routh J; Roe DJ; Garland LL; Futscher BW; Nelson MA
Sci Rep; 2024 Feb; 14(1):2939. PubMed ID: 38316884
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic Pleural Effusions: Characteristics and Discrimination From Cytology-Negative Malignant Pleural Effusions.
Park JE; Do YW; Lee DH; Lee SY; Lim JK; Choi SH; Seo HW; Yoo SS; Lee SY; Cha SI; Park JY; Lee J; Kim CH
Am J Med Sci; 2020 Sep; 360(3):236-242. PubMed ID: 32423747
[TBL] [Abstract][Full Text] [Related]
7. Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion.
Zhang H; Li C; Hu F; Zhang X; Shen Y; Chen Y; Li F
Respir Res; 2020 Oct; 21(1):284. PubMed ID: 33121490
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pro-inflammatory cytokine and pro-angiogenesis factor in differentiating malignant from benign exudative effusion.
Elhefny RA; Shaban MM; Shaker OG
Clin Respir J; 2017 Jan; 11(1):49-57. PubMed ID: 25832725
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine: new tumor marker in pleural fluid.
Santotoribio JD; Cañavate-Solano C; Garcia-de la Torre A; Del Valle-Vazquez L; Arce-Matute F; Cuadros-Muñoz JF; Sanchez del Pino MJ; Bandez-Ruiz MJ; Piñuela-Rojas C; Perez-Ramos S
Tumour Biol; 2015 Sep; 36(10):7941-5. PubMed ID: 25956279
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion.
Görgün D; Seçik F; Midilli K; Akkaya V; Yıldız P
Respir Med; 2013 Aug; 107(8):1260-5. PubMed ID: 23791464
[TBL] [Abstract][Full Text] [Related]
11. Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
Wang J; Fu J; Shen Q; Zhang F; Wang Y; Wu LL
J Clin Lab Anal; 2019 Sep; 33(7):e22943. PubMed ID: 31268191
[TBL] [Abstract][Full Text] [Related]
12. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis.
Zhu J; Feng M; Liang L; Zeng N; Wan C; Yang T; Shen Y; Wen F
BMC Cancer; 2017 Aug; 17(1):590. PubMed ID: 28854885
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
[TBL] [Abstract][Full Text] [Related]
14. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion.
Chierakul N; Kanitsap A; Chaiprasert A; Viriyataveekul R
Respirology; 2004 Mar; 9(1):66-9. PubMed ID: 14982604
[TBL] [Abstract][Full Text] [Related]
15. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in diagnosis of pleural effusion of malignant origin.
Fiorelli A; Ricci S; Feola A; Mazzella A; D'Angelo L; Santini M; Di Domenico M; Di Carlo A
Interact Cardiovasc Thorac Surg; 2016 Apr; 22(4):411-8. PubMed ID: 26769731
[TBL] [Abstract][Full Text] [Related]
17. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion.
Chen M; Xie S; Wan C; Zeng N; Wu Y; Qin J; Shen Y; Wen F
Postgrad Med; 2017 Aug; 129(6):644-648. PubMed ID: 28506100
[TBL] [Abstract][Full Text] [Related]
19. Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.
Chantharakhit C; Sujaritvanichpong N
Asian Pac J Cancer Prev; 2022 Jan; 23(1):25-31. PubMed ID: 35092368
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of haptoglobin and soluble CD163 testing for the differential diagnosis of tuberculous and malignant pleural effusions.
Gao J; Song L; Li D; Peng L; Ding H
Medicine (Baltimore); 2019 Oct; 98(42):e17416. PubMed ID: 31626097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
